National University of Singapore:製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9321)
◆英語タイトル:National University of Singapore - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9321
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:38
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:シンガポール
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
National University of Singapore (NUS) is an educational university that offers research and training services. The university provides undergraduate, graduate and double degree programmes. It offers programs in the areas of arts and social sciences, business, computing, dentistry, design and environment, engineering, integrative sciences and engineering, law, medicine, music, public health, public policy, science, and nursing. NUS also provides expeditions, internships, overseas academic exchanges, community involvement, and study abroad programmes. It has operations in Australia, Austria, Brazil, Belgium, Chile, China, Germany, Hong Kong, Ireland, Hungary, India, Ireland New Zealand, Norway, Philippines, the Netherlands, the UK and the US, among others. NUS is headquartered in Singapore.

National University of Singapore – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
National University of Singapore, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
National University of Singapore, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
National University of Singapore, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
National University of Singapore, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
National University of Singapore, Medical Devices Deals, 2012 to YTD 2018 9
National University of Singapore, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
National University of Singapore, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Annexin Pharma Enters into Collaboration Agreement with National University of Singapore 11
Ab Sciex Enters into R&D Agreement with National University of Singapore 12
Ayoxxa Biosystems Enters Into Research Agreement With NUS For Protein Analysis Technology Development 13
Licensing Agreements 14
Proteona Enters into Licensing Agreement with National University of Singapore 14
Nkarta Enters into Licensing Agreement with National University of Singapore and Jude Children’s Research Hospital 15
MediSix Therapeutics Enters into Licensing Agreement with National University of Singapore 16
Unum Therapeutics Expands Licensing Agreement with National University of Singapore and St. Jude Children’s Research Hospital 17
National University of Singapore – Key Employees 19
National University of Singapore – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Joint Venture 21
Recent Developments 22
Strategy And Business Planning 22
Nov 22, 2017: SCIEX and NUS Faculty of Science Announce Plans to Launch New Training Centre for Proteomics and Mass Spectrometry Across Asia Pacific 22
Government and Public Interest 23
Oct 08, 2018: NUS researchers uncover new role of TIP60 protein in controlling tumour formation 23
Aug 16, 2018: NUS researchers uncover a bidirectional regulator and shed light on A-to-I RNA editing in cancer cells 24
Aug 16, 2018: NUS and Harvard scientists develop novel drug that could potentially treat liver cancer more effectively 25
Aug 15, 2018: NUS study: RUNX proteins act as regulators in DNA repair 27
Apr 30, 2018: NUS researchers demystify cancer-related fatigue in breast cancer patients 29
Apr 10, 2018: Early ‘chemobrain’ intervention needed for breast cancer patients undergoing chemotherapy: NUS-led study 30
Jan 30, 2018: NUS researchers develop wireless light switch for targeted cancer therapy 32
Dec 07, 2017: NUS researchers uncover novel pathway to suppress virus-induced cancers 33
Nov 13, 2017: NUS researchers unveil mystery behind workings of blood cells 34
Sep 18, 2017: NUS scientists combine antimalarial drug with light sensitive molecules for promising treatment of cancer 35
Product News 36
Aug 14, 2018: AI technology to help design personalised combination therapy 36
Mar 01, 2018: Duke-NUS commercialises discovery to deliver therapeutics across blood brain barrier 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
National University of Singapore, Pharmaceuticals & Healthcare, Key Facts 2
National University of Singapore, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
National University of Singapore, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
National University of Singapore, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
National University of Singapore, Deals By Therapy Area, 2012 to YTD 2018 8
National University of Singapore, Medical Devices Deals, 2012 to YTD 2018 9
National University of Singapore, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Annexin Pharma Enters into Collaboration Agreement with National University of Singapore 11
Ab Sciex Enters into R&D Agreement with National University of Singapore 12
Ayoxxa Biosystems Enters Into Research Agreement With NUS For Protein Analysis Technology Development 13
Proteona Enters into Licensing Agreement with National University of Singapore 14
Nkarta Enters into Licensing Agreement with National University of Singapore and Jude Children’s Research Hospital 15
MediSix Therapeutics Enters into Licensing Agreement with National University of Singapore 16
Unum Therapeutics Expands Licensing Agreement with National University of Singapore and St. Jude Children’s Research Hospital 17
National University of Singapore, Key Employees 19
National University of Singapore, Other Locations 20
National University of Singapore, Subsidiaries 20
National University of Singapore, Joint Venture 21

List of Figures
National University of Singapore, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
National University of Singapore, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
National University of Singapore, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
National University of Singapore, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
National University of Singapore, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
National University of Singapore, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
National University of Singapore, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
National University of Singapore, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
National University of Singapore, Medical Devices Deals, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ National University of Singapore:製薬・医療:M&Aディール及び事業提携情報(National University of Singapore - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆